AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 287: R27-R32, 2004. First published March 25, 2004; doi:10.1152/ajpregu.00073.2004
0363-6119/04 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
287/1/R27    most recent
00073.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Majid, D. S. A.
Right arrow Articles by Castillo, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Majid, D. S. A.
Right arrow Articles by Castillo, A.

CALL FOR PAPERS
Oxidative Stress

Inhibition of nitric oxide synthase enhances superoxide activity in canine kidney

Dewan S. A. Majid, Akira Nishiyama, Keith E. Jackson, and Alexander Castillo

Department of Physiology, Tulane University Health Sciences Center, New Orleans, Louisiana 70112

Submitted 2 February 2004 ; accepted in final form 24 March 2004


    ABSTRACT
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
To evaluate the role of a potential interaction between superoxide anion (O2) and nitric oxide (NO) in regulating kidney function, we examined the renal responses to intra-arterial infusion of a superoxide dismutase mimetic, tempol (0.5 mg·kg–1·min–1), in anesthetized dogs treated with or without NO synthase inhibitor, N{omega}-nitro-L-arginine (NLA; 50 µg·kg–1·min–1). In one group of dogs (n = 10), tempol infusion alone for 30 min before NLA infusion did not cause any significant changes in renal blood flow (RBF; 5.2 ± 0.4 to 5.0 ± 0.4 ml·min–1·g–1), glomerular filtration rate (GFR; 0.79 ± 0.04 to 0.77 ± 0.04 ml·min–1·g–1), urine flow (V; 13.6 ± 2.1 to 13.9 ± 2.5 µl·min–1·g–1), or sodium excretion (UNaV; 2.4 ± 0.3 to 2.2 ± 0.3 µmol·min–1·g–1). Interestingly, when tempol was infused in another group of dogs (n = 12) pretreated with NLA, it caused increases in V (4.4 ± 0.4 to 9.7 ± 1.4 µl·min–1·g–1) and in UNaV (0.7 ± 0.1 to 1.3 ± 0.2 µmol·min–1·g–1) without affecting RBF or GFR. Although NO inhibition caused usual qualitative responses in both groups of dogs, the antidiuretic (47 ± 5 vs. 26 ± 4%) and antinatriuretic (67 ± 4 vs. 45 ± 11%) responses to NLA were seen much less in dogs pretreated with tempol. NLA infusion alone increased urinary excretion of 8-isoprostane (13.9 ± 2.7 to 22.8 ± 3.6 pg·min–1·g–1; n = 7), which returned to the control levels (11.6 ± 3.4 pg·min–1·g–1) during coadministration of tempol. These data suggest that NO synthase inhibition causes enhancement of endogenous O2 levels and support the hypothesis that NO plays a protective role against the actions of O2 in the kidney.

renal hemodynamics; sodium excretion; superoxide dismutase mimetic; tempol; N{omega}-nitro-L-arginine


SUPEROXIDE ANION (O2), a free radical, is a product of cellular metabolism generated due to partial reduction of molecular oxygen (5, 7). The presence of superoxide dismutase (SOD) enzyme in the living tissue usually reduces O2 generated in the body (1, 6, 13). However, recent experimental studies point to the notion that nitric oxide (NO) also acts as an antioxidative agent in the body (12, 32). In the kidney, O2 generation was also shown to cause decreases in blood flow and sodium excretion (36). Recently, we have demonstrated that SOD inhibition with diethyldithiocarbamate in anesthetized dogs reduces both renal cortical and medullary blood flow as well as urinary sodium excretion, which were significantly enhanced during NO synthase inhibition (16). These findings indicate that NO plays a protective role against the actions of O2 in the kidney. It has also been shown that O2, which is locally produced in the juxtaglomerular apparatus, limits NO signaling from the macula densa and enhances tubuloglomerular feedback responses (32, 34). Because O2 and NO are continually produced and exert opposing effects in the kidney, it is possible that the basal production of O2 and its interaction with NO are regulated physiologically in the kidney. Although O2 has been implicated in the pathogenesis of many renal diseases (1, 13, 29), the possible involvement of O2 in the physiological regulation of renal function is not yet clearly defined.

The present investigation was designed to examine the hypothesis that the O2 level in the kidney is reciprocally regulated by intrarenal NO activity and that the interaction between these free radicals influences renal hemodynamics and excretory function. In these experiments, the renal responses to scavenging of O2 elicited with intra-arterial administration of a SOD mimetic, 4-hydroxy-tetramethyl piperidime-1-oxyl (tempol), were evaluated before and during NO synthase inhibition with N{omega}-nitro-L-arginine (NLA) in anesthetized dogs (16, 17). Tempol is a low-molecular-weight nitroxide compound that is a membrane-permeable, metal-independent, stable SOD mimetic that reduces endogenous O2 levels as reported in many in vitro and in vivo studies (4, 27, 28, 32, 34).


    METHODS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
The experiments were performed in accordance with the guidelines and practices established by the Tulane University Animal Care and Use Committee.

Experiments were conducted in mongrel dogs (11–21 kg body wt) of either gender. These dogs were given supplemental amounts of sodium chloride (1.5 g·kg body wt–1·day–1 for 3 days) added to the normal laboratory diet to achieve a positive sodium balance as reported in earlier studies in our laboratory (16, 17). On the day of experiments, pentobarbital sodium was administered intravenously at 30 mg/kg body wt for induction of anesthesia and was supplemented throughout the experiment as needed. The level of anesthesia in animals was frequently checked by eliciting corneal reflex during the entire experimentation period to determine the need of supplemental doses of pentobarbital sodium. A cuffed endotracheal tube was inserted and connected to an artificial ventilator set at a rate of 18 strokes/min with a stroke volume of 15 ml/kg body wt. Body temperature was maintained within normal range using an electric heating pad. Systemic arterial pressure (SAP) was monitored via a catheter inserted into the right femoral artery and connected to a Statham pressure transducer (P23DC) and recorded on a polygraph (model 7D, Grass Instrument) as well as by the Biopac data-acquisition system. The left femoral artery was cannulated for collection of blood samples. The left jugular and the right femoral veins were cannulated for administration of inulin and isotonic saline, respectively. Isotonic saline was infused into the right femoral vein at a rate of 0.5 ml/min during the entire experimental period.

The left kidney was exposed retroperitoneally and denervated by tying and cutting all the renal nerves projecting to the kidney from the aorticorenal ganglion (15, 16, 17). Renal blood flow (RBF) was measured by placing an electromagnetic flow probe (Carolina Medical Electronics) around the renal artery, which was isolated from surrounding tissue. A curved 23-gauge needle cannula was inserted into the renal artery and connected to a pressure transducer for measurement of renal arterial pressure. Additional catheters were connected to the needle cannula for continuous infusion of heparinized saline (0.4 ml/min) as well as to prevent clotting in the cannula tip and for the intrarenal administration of drugs (tempol, NLA). Urine was collected from a catheter placed in the left ureter. After completion of the surgical procedures, a dose (1.6 ml/kg) of 2.5% solution of inulin in normal saline was administered into the jugular vein at least 45 min before the initiation of the experimental protocol followed by a continuous infusion (0.03 ml·kg–1·min–1) for the entire protocol period to determine the glomerular filtration rate (GFR).

After a stabilization period of 45 min after completion of the surgical procedures, the experimental protocol began with two consecutive 10-min urine collections. An arterial blood sample (2 ml) was collected at the midpoint of each urine collection period to measure plasma inulin, sodium, and potassium concentrations. In one group of dogs (n = 10), an infusion of tempol was initiated intra-arterially (0.5 mg·kg–1·min–1; Sigma Chemical) in the kidney and continued for the duration of the experimental period. This dose of tempol was found effective in reducing urinary 8-isoprostane (a biological marker for endogenous O2 activity) excretion in these anesthetized dog preparations (see Fig. 5). It was also reported that similar doses of tempol caused reduction in 8-isoprostane excretion rate that was associated with an effective reduction in blood pressure in spontaneously hypertensive rats (27). Ten minutes after the initiation of the tempol infusion, two 10-min urine collections were made with corresponding arterial blood sample collections. Then NLA (50 µg·kg–1·min–1; Sigma Chemical) was added to the infusion line with tempol to examine the responses to combine reduction in NO and O2 levels on renal hemodynamics and excretory function (16, 17). After 30-min combined infusion of NLA and tempol, another two consecutive 10-min urine samples were collected. In five of these dogs, tempol was infused alone for 60 min before the addition of NLA to evaluate any long-term effects of tempol on renal parameters. During this prolonged period of tempol infusion, urine samples were collected every 10 min. After this prolonged infusion, combined infusion of NLA and tempol was also made in these dogs as mentioned earlier. To examine the specificity of the O2-scavenging effects of tempol in these responses, a similar protocol was also carried out in three separate dogs with infusion of another nitroxide compound, 3-carbamyol proxyl (3-CP; 0.5 mg·kg–1·min–1; Sigma Chemical) instead of tempol. 3-CP is structurally similar to tempol, but it has minimal O2-scavenging activity (9).



View larger version (10K):
[in this window]
[in a new window]
 
Fig. 5. Effects of N{omega}-nitro-L-arginine and tempol administration on urinary excretion rate of 8-isoprostane (UISOV; A) and nitrate/nitrite (UNOxV; B) (n = 7). *P < 0.05 vs. control period; #P < 0.05 vs. N{omega}-nitro-L-arginine period.

 
In another group of dogs (n = 12), a reverse order was considered for infusions of both tempol and NLA. In these dogs, after control collection periods, an intra-arterial infusion of NLA (50 µg·kg–1·min–1) was initiated. After a 30-min infusion of NLA, two consecutive 10-min urine samples were collected. Tempol (0.5 mg·kg–1·min–1) was then added to the NLA infusion line to examine the responses to O2 scavenging during NO synthase inhibition. After 10 min of the initiation of tempol infusion, two 10-min urine collections were made during tempol plus NLA infusion. In 7 of these 12 dogs, urine samples were also collected and prepared for 8-isoprostane measurement. These urine samples were collected into glass vials containing butylated hydroxytoluene to prevent further oxidative production of 8-isoprostane during collection and preservation of the samples (19, 23, 36). The samples were kept cold during collection by packing the sample vials in insulated boxes filled with ice and then kept frozen at –70°C until analyzed. These samples were also analyzed for measuring concentration of NO metabolites, nitrate/nitrite (17). As 8-isoprostane analysis was not considered in the initial design of the protocol, urine from the other five dogs in this group and also dogs from other groups used in this study was not collected methodically and thus was not considered for this analysis. In five other dogs, 3-CP (0.5 mg·kg–1·min–1) was infused instead of tempol after infusion of NLA to examine the specificity of O2-scavenging effects on the observed responses to tempol.

At the end of each experiment, the electromagnetic flow probe was calibrated in situ by collection of timed blood samples into a graduated cylinder at different flow rates from a catheter placed in the renal artery. The kidney was then removed, stripped of all surrounding tissue, blotted dry, and weighed so that the calculated parameters could be expressed per gram of net kidney weight. Flame photometry (Instrumentation Laboratory) was used to determine the sodium and potassium concentrations in plasma and urine. Inulin concentrations in plasma and urine samples were determined by the anthrone colorimetric technique using a spectrophotometer (Ciba Corning Diagnostic). GFR was calculated using standard inulin clearance techniques. Urinary concentrations of 8-isoprostane and NO metabolites, nitrate/nitrite, were determined using enzyme immunoassay kit (Assay Design). All the data reported in RESULTS and shown in the figures are the average of the two clearance periods during each condition of the experimental protocol. Values are reported as means ± SE. Statistical comparisons of the differences in the responses within the group were conducted using one-way repeated-measures ANOVA followed by Newman-Keuls test. Comparisons of the responses between the groups were made using unpaired t-test. Differences in the mean values were deemed significant when probability values were ≤0.05.


    RESULTS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
During the control collection periods in the dogs used in the present study (n = 30), the mean values of plasma sodium, potassium, and hematocrit were 146.8 ± 1.2 meq/l, 3.5 ± 0.2 meq/l, and 45 ± 2%, respectively. There were no appreciable changes in these plasma parameters during the course of the experimental protocols.

Renal responses to tempol infusion before NLA administration. Infusion of tempol into the renal artery before NLA infusion (n = 10) did not cause any significant changes in renal parameters as illustrated in Figs. 1 and 2. There were no differences between the responses to tempol infused for 30 min (n = 5) and for 60 min (n = 5). Thus these results were pulled together and presented as a single response to tempol in the figures. It was observed that tempol infusion alone caused a slight but significant reduction in SAP (137 ± 3 to 133 ± 4 mmHg, P < 0.05). As illustrated in Figs. 1 and 2, there were no significant changes in RBF, renal vascular resistances (RVR), GFR, urine flow (V), sodium excretion (UNaV), and fractional excretion of sodium (FENa). Tempol also did not cause significant changes in urinary excretion of potassium (UKV; 0.5 ± 0.1 to 0.6 ± 0.1 µmol·min–1·g–1). After the addition of NLA to the intra-arterial infusion line with tempol for >30 min, there was an increase of 34 ± 5% (P < 0.05) in RVR and decreases of 24 ± 1% (P < 0.05) in RBF, 26 ± 8% (P < 0.05) in V, 45 ± 11% (P < 0.05) in UNaV, and 36 ± 15% (0.05 > P > 0.1) in FENa (Figs. 1 and 2) without any significant change in GFR or UKV. Addition of NLA to the tempol infusion reversed the decrease in SAP (137 ± 7 mmHg).



View larger version (9K):
[in this window]
[in a new window]
 
Fig. 1. Effects of tempol (T) infusion before N{omega}-nitro-L-arginine (N) administration on renal vascular resistance (RVR; A), renal blood flow (RBF; B) and glomerular filtration rate (GFR; C) (n = 10). Con, control period. #P < 0.05 vs. tempol period.

 


View larger version (9K):
[in this window]
[in a new window]
 
Fig. 2. Effects of tempol infusion before N{omega}-nitro-L-arginine administration on urine flow (V; A) as well as absolute (UNaV; B) and fractional excretion of sodium (FENa; C) (n = 10). #P < 0.05 vs. tempol period; @0.05 > P > 0.1 vs. tempol period.

 
Renal responses to tempol infusion in dogs pretreated with NLA. Intra-arterial infusion of NLA alone before tempol infusion (n = 12) resulted in an increase in SAP (141 ± 4 to 146 ± 4 mmHg; P < 0.05). Figures 3 and 4 illustrate the responses to NLA alone on renal hemodynamics and function. There was a decrease of 29 ± 4% (P < 0.05) in RBF and an increase of 48 ± 9% (P < 0.05) in RVR without changes in GFR. NLA infusion alone in these dogs also caused decreases of 47 ± 5% (P < 0.05) in V, 67 ± 4% (P < 0.05) in UNaV, and 61 ± 6% (P < 0.05) in FENa without a significant change in UKV (0.5 ± 0.03 to 0.5 ± 0.04 µmol·min–1·g–1). These responses to NLA were similar to those reported earlier from our laboratory (16, 17).



View larger version (10K):
[in this window]
[in a new window]
 
Fig. 3. Effects of tempol infusion after N{omega}-nitro-L-arginine administration on RVR (A), RBF (B), and GFR (C) (n = 12). *P < 0.05 vs. control period.

 


View larger version (9K):
[in this window]
[in a new window]
 
Fig. 4. Effects of tempol infusion after N{omega}-nitro-L-arginine administration on urine flow (A) as well as absolute (B) and fractional excretion of sodium (C) (n = 12). *P < 0.05 vs. control period; #P < 0.05 vs. N{omega}-nitro-L-arginine period.

 
Although tempol infusion before NLA administration did not cause appreciable changes in renal parameters (Figs. 1 and 2), administration of tempol to the NLA-pretreated dogs resulted in significant increases in V, UNaV, and FENa as illustrated in Fig. 4. However, there were no significant changes in RBF, RVR, or GFR (Fig. 3). During tempol infusion in NLA-pretreated dogs, SAP as well as UKV also did not change significantly.

Comparison of the responses to NLA before and during tempol. There were some differences in the responses to NLA between the group in which NLA was given in the presence of tempol and the group in which NLA was first administered alone before tempol infusion. It was observed that the magnitudes of the renal excretory responses to NLA in tempol-pretreated dogs were significantly less (V, 26 ± 8 vs. 47 ± 5%, P < 0.05; UNaV, 45 ± 11 vs. 67 ± 4%, P < 0.05; FENa, 36 ± 15 vs. 61 ± 6%, 0.05 > P > 0.1) than the responses observed with administration of NLA alone. However, the differences in the magnitudes of the renal hemodynamic changes to NLA (RBF, 24 ± 1 vs. 29 ± 4%; RVR, 34 ± 5 vs. 48 ± 9%) were not statistically significant.

Responses to NLA and tempol infusion on urinary 8-isoprostane and nitrate/nitrite excretion. As mentioned earlier in METHODS, the urine samples from the seven dogs in which tempol was infused after NLA administration were analyzed for 8-isoprostane and nitrate/nitrite concentration. Figure 5 illustrates these responses in urinary excretion rate of 8-isoprostane (UISOV) and nitrate/nitrite (UNOxV). It was observed that intra-arterial infusion of NLA in these seven dogs resulted in increases in UISOV. After addition of tempol to NLA infusion, UISOV returned to the control levels. As expected, NO synthase inhibition by NLA administration caused decreases in urinary excretion rate of NO metabolites (UNOxV). During coadministration of tempol and NLA, UNOxV did not change significantly from the values obtained during NLA infusion alone.

Effects of 3-CP infusion on renal hemodynamics and function. In a separate group of dogs, infusion of 3-CP either before (n = 3) or during (n = 5) infusion of NLA did not cause any appreciable changes in renal parameters. The values of RBF, GFR, V, and UNaV (4.0 ± 0.1 ml·min–1·g–1, 0.82 ± 0.10 ml·min–1·g–1, 10.5 ± 3.3 µl·min–1·g–1, and 2.3 ± 6 µmol·min–1·g–1, respectively) obtained during control periods were not significantly different during 3-CP infusion alone (4.1 ± 0.2 ml·min–1·g–1, 1.0 ± 0.2 ml·min–1·g–1, 9.5 ± 2.7 µl·min–1·g–1, and 2.0 ± 0.6 µmol·min–1·g–1, respectively). Similar to what was observed in the earlier group, intra-arterial infusion of NLA alone before 3-CP infusion in five dogs resulted in usually observed decreases in RBF (3.7 ± 0.2 to 2.8 ± 0.3 ml·min–1·g–1), V (7.6 ± 2.3 to 3.9 ± 1.6 µmol·min–1·g–1), and in UNaV (1.6 ± 0.5 to 0.8 ± 0.5 µmol·min–1·g–1) without significant changes in GFR (0.87 ± 0.17 to 0.75 ± 0.12 ml·min–1·g–1). However, in contrast to the findings with tempol infusion, 3-CP infusion in these NLA-pretreated dogs did not cause any notable changes in V (4.1 ± 1.6 µmol·min–1·g–1) and UNaV (0.7 ± 0.4 µmol·min–1·g–1), as well as in RBF (2.5 ± 0.2 ml·min–1·g–1) and GFR (0.71 ± 0.12 ml·min–1·g–1).


    DISCUSSION
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
In the present study, it has been observed that intra-arterial administration of an SOD mimetic, tempol, causes diuretic and natriuretic responses in dogs pretreated with NLA but not in the intact condition before NO inhibition. Infusion of another nitroxide compound (3-CP) having similar chemical structure as tempol but with minimal SOD mimetic activity (9) did not cause such changes in renal excretory function in NLA-treated dogs, indicating that these responses to tempol were linked to its O2-scavenging effect. The dose of tempol used in this study was seen as sufficient to normalize the enhanced 8-isoprostane excretion rate (Fig. 5A) during NO blockade, indicating its maximal efficacy as an antioxidant. The dose for NLA was also used to achieve maximal inhibition of renal NO formation as in other studies conducted in our laboratory (16, 17). As 8-isoprostane excretion is considered as a marker for endogenous O2 activity (19, 23, 24), this finding indicates that the reduction in NO level facilitates the increment in O2 activity in the kidney. Urinary excretion of NO metabolites, nitrates/nitrites (UNOxV), decreased during NLA administration as expected and remained unchanged during coadministration of NLA and tempol (Fig. 5B). As scavenging of O2 by tempol in NLA-pretreated dogs caused diuresis and natriuresis without changing UNOxV, it is conceivable that such changes in excretory function were not related to NO but to the reduction in O2 level. It was also noted that pretreatment with tempol generally attenuated the excretory responses to NLA administration. These findings suggest that the renal excretory responses to NO synthase inhibition are at least partially influenced by the concomitant enhancement of endogenous O2 level.

There is a possibility that these effects of tempol may be linked to its action on renal sympathetic nerves (30) or antioxidant-induced changes in the release of norepinephrine from the nerve terminals (14). However, the present experiments were conducted in denervated kidneys to minimize any influence from concomitant alterations in renal sympathetic activity. The procedure for renal denervation employed in the present study was previously shown to completely abolish the changes in renal variables due to elicitation of cardiovascular reflexes that are mediated by alteration in renal sympathetic nerve (15). In the present study, we did not look at the possible changes in any humoral factor(s) in response to tempol administration. However, the involvement of such possible humoral factor(s) in the responses to tempol in the present study seems unlikely as we did not observe any appreciable changes in renal parameters during tempol infusion before NO inhibition. Further experiments may be needed to clarify this issue. It may also be argued that these renal responses to tempol may be attributed to the possible formation of H2O2 due to the use of this SOD mimetic (4). However, such possibility is unlikely as it has been reported that the effect of H2O2 is rather antidiuretic and antinatriuretic (4), an effect opposite to what has been observed in the present study.

The fact that there were no appreciable changes in renal parameters during tempol administration before NO inhibition (Figs. 1 and 2) indicates that the basal tissue concentration of O2 may be kept to a minimal level in the intact condition due to efficient antioxidant effect of endogenous NO (3, 8, 18), and thus there would be no O2-scavenging effects of tempol. In other studies in rats (27, 28), it was also demonstrated that tempol administration had no significant effect on systemic blood pressure in Wistar-Kyoto rats but caused hypotension in spontaneously hypertensive rats. The results of the present investigation and from others (27, 28) indicate that the effects of scavenging O2 depend on the existing endogenous level of O2 production in the experimental animal. Although no supportive evidence is currently available, it can be speculated that the function of the enzymes responsible for endogenous production of O2 may be limited by intact NO synthase activity, and these oxidative enzymes may become upregulated during NO synthase inhibition. Another recent study from our laboratory has also demonstrated functional evidence for the presence of enhanced NO bioactivity in mice lacking the gene for gp91PHOX subunit of NAD(P)H oxidase (11). Thus it is reasonable to speculate that a disruption of NO synthase activity may be critically linked to an upregulation of NAD(P)H oxidase and/or other oxidative enzymes.

It was observed that tempol-induced increases in urine flow and sodium excretion in NO-inhibited dogs occurred in the absence of changes in RBF or GFR (Figs. 3 and 4). Previous studies have also shown that SOD inhibition (enhancement of O2 level) in dogs could cause reductions in urine flow and sodium excretion without appreciable changes in RBF or GFR (16). Collectively, these data demonstrate that intrarenal O2 can exert a direct influence on renal tubular reabsorptive function, leading to water and sodium retention. The exact mechanism by which O2 can induce antidiuresis and antinatriuresis is not yet clear. However, studies using isolated tubule preparation by Ortiz and Garvin (22) have shown that O2 can stimulate NaCl reabsorption by the thick ascending limb through a mechanism that is linked to protein kinase C activation in the epithelial cells. The findings in the present investigation clearly demonstrated that endogenous O2 exerts such direct action on tubular reabsorptive function primarily under conditions of reduced NO activity. These results are in agreement with our previous findings that the renal excretory responses to SOD inhibition are enhanced during NO synthase inhibition and provide further support to the renoprotective role of NO over the actions of endogenous O2 (16).

8-Isoprostane is generally believed to be formed endogenously due to oxidation of membrane phospholipids by a potent oxidant, peroxynitrite, that is produced during in vivo chemical reaction between NO and O2 (2, 10, 24). However, we observed an increase in urinary excretion of 8-isoprostane when endogenous NO production was inhibited by NLA administration (Fig. 5). This increase in 8-isoprostane excretion was ameliorated completely by the O2 scavenger tempol, indicating that such increased formation of 8-isoprostane may be the result of direct peroxidation of lipids by O2 (19, 23). Although tempol infusion normalized the enhanced excretion rate of 8-isoprostane and caused somewhat of a reversal of renal excretory responses to NO inhibition (Figs. 4 and 5), it did not cause reversal of the vasoconstrictor response to NLA administration (Fig. 3). This finding may not be entirely unexpected as the improvement of endothelial dysfunction due to the scavenging of endogenous O2 has been suggested to be linked with enhanced NO bioavailability (18, 35). In other words, the vasodilator effect of scavenging O2 is primarily due to the action of NO in the vasculature. Thus tempol administration during effective blockade of NO synthase is not expected to cause a renal vasodilator effect. It may be argued that the applied dose of tempol might have been insufficient to cause a vasodilatory effect. However, this possibility is unlikely as this dose of tempol was maximally effective in reducing the increased level of 8-isoprostane excretion to a near control value. The fact that tempol did not cause any vascular effect despite its effective blockade of enhanced O2 activity during NLA administration suggests that NO inhibition exerted a dominant effect over the action of O2 in mediating renal vasoconstriction.

In conclusion, the results of the present investigation indicate that under conditions of reduced NO activity there is an increase in endogenous O2 level that influences renal excretory function. These data further support the hypothesis that endogenous NO provides a renoprotective effect against the actions of O2 by acting as an antioxidative agent and thus suggest an interactive role for NO and O2 in the physiological regulation of kidney function.

Perspectives

The findings in the present study and also from our previous study (16) indicate an important role for O2 and its interaction with NO in the regulation of renal function. It has been shown that NO activity in many biological systems is enhanced by addition of the enzyme SOD, suggesting that interactions of O2 and NO are a frequent occurrence in biological tissues (21, 25). Importance of O2 and NO interaction in the regulation of many biological events has been increasingly appreciated due to the fact that under normal conditions, O2 is a constant product of cellular metabolism (1, 6, 13). In fact, it was proposed in 1989 (31) that vascular endothelium had an intrinsic capacity to generate O2 for regulatory purposes such as inactivation of NO. As a gaseous free radical, NO is highly reactive with other free radicals such as O2 (10); thus it could be argued that the free radical reactivity of NO is in many ways an important physiological regulator of cellular function in vivo. It has been demonstrated that NO has an antiatherosclerotic effect by acting as a powerful inhibitor of membrane lipid peroxidation because of its ability to scavenge O2 (3, 20, 26). Previous studies also provided evidence that NO reacts with oxygen free radicals and thus antagonizes the prooxidant properties of heme proteins in the biological tissues (8). An NO donor has also been shown to provide a cytoprotective effect in the ischemic tissue by reacting with excess oxygen free radicals in ischemia-reperfusion injuries (18). Thus it is conceivable that the interaction between NO and O2 has a role in maintaining a desired state of balance between oxidative and antioxidative processes in the kidney, any imbalance of which would lead to derangements in renal function.


    GRANTS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
This study was supported by National Heart, Lung, and Blood Institute Grants HL-51306 and HL-66432.


    ACKNOWLEDGMENTS
 
We are grateful to K. A. Taher and Dr. M. Z. Haque for technical assistance and D. Olavarrieta for excellent secretarial support in preparing the manuscript.

Present address for A. Nishiyama: Dept. of Pharmacology, Kogawa Medical University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan (E-mail: akira@kms.ac.jp).


    FOOTNOTES
 

Address for reprint requests and other correspondence: D. S. A. Majid, Dept. of Physiology, SL 39, Tulane Univ. Health Sciences Center, 1430 Tulane Ave., New Orleans, LA 70112 (E-mail: majid{at}tulane.edu).


    REFERENCES
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Baud L and Ardaillou R. Reactive oxygen species: production and role in the kidney. Am J Physiol Renal Fluid Electrolyte Physiol 251: F765–F776, 1986.[Abstract/Free Full Text]
  2. Beckman JS and Crow JP. Pathological implications of nitric oxide, superoxide, and peroxinitrite formation. Biol Soc Transact 21: 330–334, 1993.
  3. Cannon RO III. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem 44: 1809–1819, 1998.[Abstract/Free Full Text]
  4. Chen YF, Cowley AW, and Zou AP. Increased H2O2 counteracts the vasodilator and natriuretic effects of superoxide dismutation by tempol in renal medulla. Am J Physiol Regul Integr Comp Physiol 285: R827–R833, 2003.[Abstract/Free Full Text]
  5. Commoner B, Townsend J, and Pake GE. Free radicals in biological materials. Nature 174: 689–691, 1954.[Medline]
  6. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 82: 47–95, 2002.[Abstract/Free Full Text]
  7. Fridovich I. The biology of oxygen radicals. Science 201: 875–880, 1978.[Abstract/Free Full Text]
  8. Gorbunov NV, Osipov AN, Day BW, Zayas-Rivera B, Kagan VE, and Elsayed NM. Reduction of ferrylmyoglobin and ferrylhemoglobin by nitric oxide: a protective mechanism against ferryl hemoprotein-induced oxidations. Biochemistry 34: 6689–6699, 1995.[CrossRef][Medline]
  9. Hahn SM, Sullivan FJ, Deluca AM, Bacher JD, Liebmann Krisna MC, Coffin D, and Mitchell JB. Hemodynamic effect of the nitroxide superoxide dismutase mimetics. Free Radic Biol Med 27: 529–535, 1999.[CrossRef][ISI][Medline]
  10. Halliwell B, Zhao K, and Whiteman M. Nitric oxide, and peroxynitrite. The ugly, the uglier and the not so good: a personal view of recent controversies. Free Radic Res 31: 651–669, 1999.[ISI][Medline]
  11. Haque MZ and Majid DSA. Assessment of renal functional phenotype in mice lacking gp91PHOX subunit of NAD(P)H oxidase. Hypertension 43: 1–6, 2004.[Free Full Text]
  12. Huie RE and Padmaja S. The reaction of NO with superoxide. Free Radic Res Commun 18: 195–199, 1993.[ISI][Medline]
  13. Ichikawa I, Kiyama S, and Yoshioka T. Renal antioxidant enzymes: their regulation and function. Kidney Int 45: 1–9, 1994.[ISI][Medline]
  14. Jou SB and Cheng JT. The role of free radicals in the release of noradrenaline from myenteric nerve terminals of guinea-pig ileum. J Auton Nerv Syst 66: 126–130, 1997.[CrossRef][ISI][Medline]
  15. Karim F, Majid DSA, and Summerill RA. Sympathetic nerves in the mediation of renal response to localized stimulation of atrial receptors in anesthetized dogs. J Physiol 417: 63–78, 1989.[Abstract/Free Full Text]
  16. Majid DS and Nishiyama A. Nitric oxide blockade enhances renal responses to superoxide dismutase inhibition in dogs. Hypertension 39: 293–297, 2002.[Abstract/Free Full Text]
  17. Majid DSA, Omoro SA, Chin SY, and Navar LG. Intrarenal nitric oxide activity and pressure natriuresis in anesthetized dogs. Hypertension 32: 266–272, 1998.[Abstract/Free Full Text]
  18. Mason RB, Pluta RM, Walbridge S, Wink DA, Oldfield EH, and Boock RJ. Production of reactive oxygen species after reperfusion in vitro and in vivo: protective effect of nitric oxide. J Neurosurg 93: 99–107, 2000.[ISI][Medline]
  19. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, and Roberts LJ II. A series of prostaglandins F2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 87: 9383–9387, 1990.[Abstract/Free Full Text]
  20. O'Donnell VB, Chumley PH, Hogg N, Bloodsworth A, Darley-Usmar VM, and Freeman BA. Nitric oxide inhibition of lipid peroxidation: kinetics of reaction with lipid peroxyl radicals and comparison with {alpha}-tocopherol. Biochemistry 36: 15216–15223, 1997.[CrossRef][Medline]
  21. Omar HA, Cherry PD, Mortelliti MP, Burke-Wolin T, and Wolin MS. Inhibition of coronary artery superoxide dismutase attenuates endothelium-dependent and -independent nitrovasodilator relaxation. Circ Res 69: 601–608, 1991.[Abstract/Free Full Text]
  22. Ortiz PA and Garvin JL. Superoxide stimulates NaCl absorption by the thick ascending limb. Am J Physiol Renal Physiol 283: F957–F962, 2002.[Abstract/Free Full Text]
  23. Practico D, Lawson JA, Roakach J, and FitzGerald GA. The isoprostanes in biology and medicine. Trends Endocrinol Metab 12: 243–247, 2001.[CrossRef][ISI][Medline]
  24. Romero JC and Rackelhoff JF. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 34: 943–949, 1999.[Abstract/Free Full Text]
  25. Rubanyi GM and Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol Heart Circ Physiol 250: H822–H827, 1986.[Abstract/Free Full Text]
  26. Rubbo H, Radi R, Trujillo M, Telleri R, Kalyanaraman B, Barnes S, Kirk M, and Freeman BA. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem 269: 26066–26075, 1994.[Abstract/Free Full Text]
  27. Schnackenberg CG, Welch WJ, and Wilcox CS. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic. Role of nitric oxide. Hypertension 32: 59–64, 1998.[Abstract/Free Full Text]
  28. Schnackenberg CG and Wilcox CS. Two-week administration of tempol attenuates both hypertension and renal excretion of I-iso prostaglandin F2{alpha}. Hypertension 33: 424–428, 1999.[Abstract/Free Full Text]
  29. Shah SV. Role of reactive oxygen metabolites in experimental glomerular disease. Kidney Int 35: 1093–1106, 1989.[ISI][Medline]
  30. Shokoji T, Nishiyama A, Fujisawa Y, Hitomi H, Kiyomoto H, Takahashi N, Kimura S, Kohno M, and Abey Y. Renal sympathetic nerve responses to tempol in spontaneously hypertensive rats. Hypertension 41: 266–273, 2003.[Abstract/Free Full Text]
  31. Vanhouttee PM. Endothelium and control of vascular function. State of the Art lecture. Hypertension 13: 658–667, 1989.[Abstract/Free Full Text]
  32. Welch WJ, Tojo A, and Wilcox CS. Roles of NO and oxygen radicals in tubuloglomerular feedback in SHR. Am J Physiol Renal Physiol 278: F769–F776, 2000.[Abstract/Free Full Text]
  33. Wennmalm A, Benthin G, Edlund A, Jungersten L, Kieler-Jensen N, Lundin S, Westfelt UN, Petersson AS, and Waagstein F. Metabolism and excretion of nitric oxide in humans. An experimental and clinical study. Circ Res 73: 1121–1127, 1993.[Abstract/Free Full Text]
  34. Wilcox CS and Welch WJ. Interaction between nitric oxide and oxygen radicals in regulation of tubuloglomerular feedback. Acta Physiol Scand 168: 119–124, 2000.[CrossRef][ISI][Medline]
  35. Wolin MS, Gupte SA, Iesaki T, and Mohazzab-HKM. Oxidant and vascular nitric oxide signalling. In: Nitric Oxide and the Regulation of the Peripheral Circulation, edited by Kadowitz PJ and McNamara DB. Boston, MA: Birkhauser, 2000, p. 33–48.
  36. Zou AP, Li N, and Cowley AW Jr. Production and actions of superoxide in the renal medulla. Hypertension 37: 547–553, 2001.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
M. Z. Haque and D. S. A. Majid
Reduced renal responses to nitric oxide synthase inhibition in mice lacking the gene for gp91phox subunit of NAD(P)H oxidase
Am J Physiol Renal Physiol, September 1, 2008; 295(3): F758 - F764.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
A. Just, C. L. Whitten, and W. J. Arendshorst
Reactive oxygen species participate in acute renal vasoconstrictor responses induced by ETA and ETB receptors
Am J Physiol Renal Physiol, April 1, 2008; 294(4): F719 - F728.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. M. Moreno, I. Rodriguez Gomez, R. Wangensteen, M. Alvarez-Guerra, J. d. D. Luna, J. Garcia-Estan, and F. Vargas
Tempol improves renal hemodynamics and pressure natriuresis in hyperthyroid rats
Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R867 - R873.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
S. Wesseling, J. A. Joles, H. van Goor, H. A. Bluyssen, P. Kemmeren, F. C. Holstege, H. A. Koomans, and B. Braam
Transcriptome-based identification of pro- and antioxidative gene expression in kidney cortex of nitric oxide-depleted rats
Physiol Genomics, January 17, 2007; 28(2): 158 - 167.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Just, A. J. M. Olson, C. L. Whitten, and W. J. Arendshorst
Superoxide mediates acute renal vasoconstriction produced by angiotensin II and catecholamines by a mechanism independent of nitric oxide
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H83 - H92.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. B. Silva, P. A. Ortiz, N. J. Hong, and J. L. Garvin
Superoxide Stimulates NaCl Absorption in the Thick Ascending Limb Via Activation of Protein Kinase C
Hypertension, September 1, 2006; 48(3): 467 - 472.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
U. K. Dutta, J. Lane, L. J. Roberts II, and D. S. A. Majid
Superoxide formation and interaction with nitric oxide modulate systemic arterial pressure and renal function in salt-depleted dogs.
Experimental Biology and Medicine, March 1, 2006; 231(3): 269 - 276.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L. Kopkan and D. S.A. Majid
Enhanced Superoxide Activity Modulates Renal Function in NO-Deficient Hypertensive Rats
Hypertension, March 1, 2006; 47(3): 568 - 572.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
L. Kopkan, A. Castillo, L. G. Navar, and D. S. A. Majid
Enhanced superoxide generation modulates renal function in ANG II-induced hypertensive rats
Am J Physiol Renal Physiol, January 1, 2006; 290(1): F80 - F86.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L. Kopkan and D. S. A. Majid
Superoxide Contributes to Development of Salt Sensitivity and Hypertension Induced by Nitric Oxide Deficiency
Hypertension, October 1, 2005; 46(4): 1026 - 1031.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
D. S. A. Majid, A. Nishiyama, K. E. Jackson, and A. Castillo
Superoxide scavenging attenuates renal responses to ANG II during nitric oxide synthase inhibition in anesthetized dogs
Am J Physiol Renal Physiol, February 1, 2005; 288(2): F412 - F419.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
287/1/R27    most recent
00073.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Majid, D. S. A.
Right arrow Articles by Castillo, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Majid, D. S. A.
Right arrow Articles by Castillo, A.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.